对欧洲生物制品市场（包括生物类似药）的新见解。
Emerging Insights into European Markets of Biologics, Including Biosimilars.
作者信息
Simoens Steven, Huys Isabelle
机构信息
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
出版信息
Pharmaceuticals (Basel). 2022 May 17;15(5):615. doi: 10.3390/ph15050615.
Abstract
Biological medicinal products have revolutionised the treatment of many diseases, e [...].
摘要
生物药品已经彻底改变了许多疾病的治疗方式，例如…… （原文不完整，只能翻译到这里）
相似文献
1
Emerging Insights into European Markets of Biologics, Including Biosimilars.对欧洲生物制品市场（包括生物类似药）的新见解。
Pharmaceuticals (Basel). 2022 May 17;15(5):615. doi: 10.3390/ph15050615.
2
Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.生物类似药与专利生物药之间的竞争：借鉴欧洲和日本的经验
Pharmacoeconomics. 2016 Nov;34(11):1173-1186. doi: 10.1007/s40273-016-0428-6.
3
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!识别欧洲非专利生物制品和生物类似药市场的关键优势：不仅仅是价格！
BioDrugs. 2020 Apr;34(2):159-170. doi: 10.1007/s40259-019-00395-w.
4
Upcoming Drifts in Bio-similars.生物类似药的未来发展趋势。
Curr Rev Clin Exp Pharmacol. 2021;16(1):39-51. doi: 10.2174/1574884715666200507131943.
5
The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.生物制品和生物类似药在美国日益重要的作用：来自美国药师协会生物制品和生物类似药利益相关者会议的观点
J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):e15-e27. doi: 10.1016/j.japh.2017.05.014. Epub 2017 Jul 6.
6
The economics of biosimilars.生物类似药的经济学
Am Health Drug Benefits. 2013 Sep;6(8):469-78.
7
The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.生物类似药的概念：从特性鉴定到演变——一篇叙述性综述。
Oncologist. 2018 Mar;23(3):346-352. doi: 10.1634/theoncologist.2017-0126. Epub 2017 Dec 28.
8
Biologics and biosimilars.生物制品和生物类似药。
J Dermatolog Treat. 2015;26(4):299-302. doi: 10.3109/09546634.2015.1054782. Epub 2015 Jun 24.
9
Challenges With the Development of Biosimilars in Asia for Western Markets: An Overview and Suggested Solutions.亚洲生物类似药面向西方市场研发的挑战：综述与建议解决方案
Ther Innov Regul Sci. 2017 Mar;51(2):200-206. doi: 10.1177/2168479016668377. Epub 2016 Sep 27.
10
Development and regulation of biosimilars: current status and future challenges.生物类似药的研发与监管：现状与未来挑战。
BioDrugs. 2013 Jun;27(3):203-11. doi: 10.1007/s40259-013-0020-y.
引用本文的文献
1
Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries.生物类似药引入对甘精胰岛素价格的影响：28个欧洲国家的回顾性分析
BMJ Open. 2025 Jan 30;15(1):e090484. doi: 10.1136/bmjopen-2024-090484.
2
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study.比利时专利过期生物药品处方决策的决定因素：一项定性研究。
BMC Health Serv Res. 2022 Sep 29;22(1):1211. doi: 10.1186/s12913-022-08591-1.
本文引用的文献
1
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.欧洲非专利生物制品和生物类似药招标——迈向更可持续做法的建议
Pharmaceuticals (Basel). 2021 May 24;14(6):499. doi: 10.3390/ph14060499.
2
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study.模拟静脉注射生物类似物曲妥珠单抗与皮下注射对照曲妥珠单抗治疗HER2阳性乳腺癌辅助治疗的成本：一项比利时案例研究。
Pharmaceuticals (Basel). 2021 May 11;14(5):450. doi: 10.3390/ph14050450.
3
The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?比利时的非专利生物制品市场：医疗系统是否在给公平市场竞争制造障碍？
Pharmaceuticals (Basel). 2021 Apr 10;14(4):352. doi: 10.3390/ph14040352.
4
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.2009 - 2019年西班牙生物类似药产品的预算影响分析
Pharmaceuticals (Basel). 2021 Apr 9;14(4):348. doi: 10.3390/ph14040348.
5
Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities.四个主要监管机构对一个包含八项生物类似药产品批准的单一组合所应用的监管科学分析。
Pharmaceuticals (Basel). 2021 Apr 1;14(4):306. doi: 10.3390/ph14040306.
6
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain.西班牙临床治理背景下生物类似药处方激励措施的障碍
Pharmaceuticals (Basel). 2021 Mar 22;14(3):283. doi: 10.3390/ph14030283.
7
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars.阿达木单抗生物类似药欧洲公共评估报告中描述的（潜在关键）质量属性的信息类型与范围
Pharmaceuticals (Basel). 2021 Feb 25;14(3):189. doi: 10.3390/ph14030189.
8
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations.向患者介绍生物类似药：欧洲患者协会的作用。
Pharmaceuticals (Basel). 2021 Feb 4;14(2):117. doi: 10.3390/ph14020117.
9
Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria.生物类似药的引入是否影响了其价格和使用情况？以保加利亚的生物抗风湿药物（bDMARD）为例。
Pharmaceuticals (Basel). 2021 Jan 14;14(1):64. doi: 10.3390/ph14010064.
10
Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.欧洲生物类似药的可持续性：基于系统文献综述的德尔菲小组共识
Pharmaceuticals (Basel). 2020 Nov 17;13(11):400. doi: 10.3390/ph13110400.
Zotero 插件